| Title: |
Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series |
| Authors: |
Beringheli, Tomaso; Javaux, Clément; Roux, Sandrine; Braun, Evelyne; Chauvelot, Pierre; Goutelle, Sylvain; Briot, Thomas; Cottin, Judith; Dupieux, Céline; Boulant, Johanna; Conrad, Anne; Ader, Florence; Ferry, Tristan; Valour, Florent; Triffault-Filit, Claire; Becker, Agathe; Eberl, Isabelle; Lippman, Joanna-Isabelle Kurban Bessa; Van-Den-Bogaart, Lorena; Simon, Marie; Bahuaud, Olivier; Soueges, Sarah; Landre, Sophie; Perpoint, Thomas; Wan, Marie; Batailler, Cécile; Lustig, Sébastien; Servien, Elvire; Delfosse, Gerald; Mesnard, Guillaume; Baltzer, Jean; Erard, Julien; Cance, Nicolas; Martres, Sébastien; Trouillet, Franck; Gunst, Stanislas; Couraudon, Alexandre; Viste, Anthony; Ewald, Fabien; Besse, Jean-Luc; Cotte, Matthieu; Fessy, Michel; Chaudier, Philippe; Cuinet, Thomas; Derreveaux, Vianney; Bertani, Antoine; Colas, Antoine; Rongieras, Frédéric; Masson, Jean-Baptiste; Vézole, Léonard; Rarchaert, Maxime; Pibarot, Vincent; Gazarian, Aram; Walch, Arnaud; Gaillard, Christophe; Vanpoulle, Gaetan; Ducharne, Louis; Ly, Lyliane; Ben-Hadid, Nael; Lahlali, Selma; Druel, Thibault; Rutka, Victor; Mojallal, Alain-Ali; Hashim, Abdulrahman; Henry, Guillaume; Person, Hélène; Lherm, Mathilde; Chevreau-Ciliberti, Audrey; Macabéo, Caroline; Aubrun, Frédéric; Rouhana, Kaissar; Dziadzko, Mikhail; Roussel-Gaillard, Tiphaine; Beraud, Laetitia; Curtil-Dit-Galin, Matthieu; Horikian, Ani; Maucotel, Anne-Lise; Kolenda, Camille; Rasigade, Jean-Philippe; Trecourt, Alexis; Gicquel, David; Vervust, Grégoire; Morelec, Isabelle; Pialat, Jean-Baptiste; Lavigne, Joris; Stacoffe, Nicolas; Henry, Agnes; Vieux, Noémie; Garreau, Romain |
| Contributors: |
Hôpital de la Croix-Rousse CHU - HCL; Hospices Civils de Lyon (HCL); Lyon Bone and Joint Infection Study Group (BJI); Université Claude Bernard Lyon 1 - Institut des Sciences Pharmaceutiques et Biologiques (UCBL ISPB); Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon; Evaluation et modélisation des effets thérapeutiques LBBE; Département biostatistiques et modélisation pour la santé et l'environnement LBBE; Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE); Université de Lyon-Université de Lyon-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE); Université de Lyon-Université de Lyon-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS); Université de Lyon; Laboratoire d'automatique, de génie des procédés et de génie pharmaceutique (LAGEPP); Université de Lyon-Université de Lyon-École Supérieure de Chimie Physique Électronique de Lyon (CPE)-Centre National de la Recherche Scientifique (CNRS); Centre Hospitalier Lyon Sud CHU - HCL (CHLS); Pathogénie des Staphylocoques – Staphylococcal Pathogenesis CIRI (CIRI-StaPath); Centre International de Recherche en Infectiologie (CIRI); École normale supérieure de Lyon (ENS de Lyon); Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon); Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS); Pathogenèse des légionelles- Legionella pathogenesis CIRI (CIRI-LegioPath); Centre d'investigation clinique Neurosciences CHU Pitié Salpêtrière (CIC Neurosciences); Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Service de Maladies Infectieuses et Tropicales Hôpital de la Croix-Rousse - HCL; Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL); Laboratoire de Biomécanique et Mécanique des Chocs (LBMC UMR T9406); Université de Lyon-Université de Lyon-Université Gustave Eiffel |
| Source: |
ISSN: 0305-7453. |
| Publisher Information: |
CCSD; Oxford University Press (OUP) |
| Publication Year: |
2025 |
| Collection: |
Université Jean Monnet – Saint-Etienne: HAL |
| Subject Terms: |
[SDV]Life Sciences [q-bio] |
| Description: |
International audience ; Abstract Background and objectives Due to its potentially better long-term haematologic tolerance compared to linezolid, tedizolid represents an attractive option for prolonged antibiotic therapy in complicated/chronic Gram-positive infections. However, there is little information regarding the risk of peripheral neurological toxicity, representing another obstacle to the extended use of oxazolidinones. Reporting neurologic adverse events occurring during tedizolid therapy for chronic implant-associated infections. Patients and methods Patients experiencing tedizolid-associated neurologic adverse events were retrospectively described in a case series. Results Five patients (four males; age range, 65–75 years) receiving tedizolid (200 mg q24h) as long-term suppressive therapy for chronic implant-associated infection presented with peripheral neuropathy. In four cases, tedizolid was used after discontinuation of linezolid for toxicity, including one case of neuropathy. Three had at least one additional risk factor for neuropathy (including two diabetes, one of them with diabetes-related nephropathy). Neuropathic symptoms [paraesthesia (n = 2), worsening of pre-existing neuropathy (n = 2), dysesthesias (n = 1)] appeared after a median of 12.4 (IQR, 8.2–13.3) months of tedizolid treatment. Electromyoneurography (EMNG) confirmed axonal sensory polyneuropathy in all but one patient for which EMNG was still within normal ranges, but compatible with incipient neurotoxicity. Tedizolid was stopped in all patients, three patients required specific treatment for neuropathic pain. At last follow-up [2.4 (IQR, 1–2.5) years from tedizolid discontinuation], clinical recovery from neuropathy was noted in three patients. The two patients with persistent neuropathy symptoms were diabetic; one showed EMNG improvement. Conclusions Prolonged used of tedizolid may be associated with peripheral neurologic toxicity, which should be monitored in at-risk patients. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/jac/dkaf315 |
| Availability: |
https://hal.science/hal-05227623; https://doi.org/10.1093/jac/dkaf315 |
| Accession Number: |
edsbas.9DAE14AA |
| Database: |
BASE |